|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Amgen_Ventures
|
|
gptkbp:awards
|
numerous industry awards
|
|
gptkbp:business_model
|
B2 B and B2 C
|
|
gptkbp:ceo
|
gptkb:Mark_Lee
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:collaborations
|
academic institutions
pharmaceutical companies
|
|
gptkbp:data_type
|
clinical data
patient data
genomic data
proteomic data
metabolomic data
|
|
gptkbp:focus
|
early cancer detection
|
|
gptkbp:founded
|
gptkb:2014
|
|
gptkbp:founder
|
gptkb:Gabriel_Otte
|
|
gptkbp:future_plans
|
global expansion
expand product offerings
enhance technology
increase clinical trials
|
|
gptkbp:goal
|
improve patient outcomes
|
|
gptkbp:headquarters
|
gptkb:South_San_Francisco,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Freenome
|
|
gptkbp:impact
|
personalized medicine
early detection of cancer
improved treatment options
reduction in cancer mortality
|
|
gptkbp:invention
|
multiple patents filed
|
|
gptkbp:investment
|
gptkb:The_Venture_Reality_Fund
gptkb:Bessemer_Venture_Partners
gptkb:Andreessen_Horowitz
gptkb:Canaan_Partners
gptkb:Data_Collective_DCVC
gptkb:Google_Ventures
|
|
gptkbp:market
|
global cancer diagnostics market
|
|
gptkbp:mission
|
transform cancer care
|
|
gptkbp:partnership
|
gptkb:healthcare_organization
|
|
gptkbp:products
|
blood test for cancer
|
|
gptkbp:publishes
|
scientific publications
|
|
gptkbp:receives_funding_from
|
over $200 million
|
|
gptkbp:regulatory_compliance
|
CLIA certified laboratory
FDA approved tests
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
multi-omics
|
|
gptkbp:technology
|
gptkb:software_framework
gptkb:item
biomarker discovery
diagnostic tests
cancer screening
|
|
gptkbp:user_base
|
gptkb:physicist
healthcare providers
laboratories
patients
oncologists
|